Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Adderall XR Prescribers (US)

Articles with lock require a subscription to GLG News | Request a free trial
January 16, 2008
Sanofi's Gardasil Should Be As Widely Accepted in Europe as in US
Analysis of: France Backs Sanofi's HPV Vaccine Gardasil Over Glaxo's | online.wsj.com
Author: GLG Expert Contributor
Sanofi's Gardisil, the first-to-market HPV vaccine for adolescent females, has been fairly widely accepted in the US, albeit with some concerns regarding adverse reactions and cost.  It is likely that EU sales will gradually increase as the vaccine is accepted in Europe as well.
December 19, 2007
Results of phase 1 trial, on treatment of parkinson's disease, presented @ scientific forum
Analysis of: Ceregene Presents Long-Term Follow-Up from Phase 1 Trial of CERE-120 in Parkinson's Disease | www.pipelinereview.com
Author: GLG Expert Contributor
This is a very significant event for Ceregene.  Previous studies, with drug treatment, on treatment for parkinsons have shown that the placebo effect only lasts for three months.  The symptoms of Parkinson's  increase 5-10% per year( as part of the natural progression of the disorder). ...
December 17, 2007
Delivery of nerve growth factor to the brain is in infant stage of research
Analysis of: Gene A/S begins Phase Ib clinical trial with NsG0202 for the treatment of Alzheimer's disease | www.pipelinereview.com
Author: GLG Expert Contributor
Nerve growth factor has some connection to Alzheimer's but the mechanism is not clear.  In Alzheimer's, nerve growth factor is actually increased in the brain, EXCEPT, in the nucleus basalis, and this may be crucial.  Will this delivery system get it there?  And then, will it work?
Louis SanfilippoDecember 11, 2007
Agomelatine, An Antidepressant Without Weight Gain and Sexual Side Effects?
Analysis of: Novel Melatonergic Antidepressant Remains Promising | www.clinicalpsychiatrynews.com
Author: Louis Sanfilippo, President, LCS Group, LLC
Agomelatine (Valdoxan; Servier with rights in Europe and Novartis in the US) is a mixed melatonin (MT1 and MT2) agonist and serotonin 5-HT2c antagonist in development as a treatment for major depression and generalized anxiety disorder.  Its melatonergic properties make it unique among antidepressant...
December 10, 2007
Use of Intranasal Desmopressin Already on the Decline
Analysis of: Desmopressin Acetate (marketed as DDAVP Nasal Spray, DDAVP Rhinal Tube, DDAVP, DDVP, Minirin, and Stimate Nasal Spray) | www.fda.gov
Author: GLG Expert Contributor
Intranasal desmopressin is rarely used now for nocturnal enuresis.  Most pediatricians have already converted to oral formulations.
December 3, 2007
FDA approval, if obtained, for use of Lexapro in adolescents will matter to Lexapro/Forest
Analysis of: Forest Laboratories and Lundbeck announces positive results of Lexapro(R) phase III study in adolescents with major depression | www.pipelinereview.com
Author: GLG Expert Contributor
If this study leads to FDA approval of Lexapro for use in adolescents it should lead to an increase in its use overall, by psychiatrists and by primary care physicians, including pediatricians.
November 30, 2007
Meridian's Point-of-Care Testing Should Find a Home in Pediatric Offices
Analysis of: Meridian Bioscience Receives FDA Clearance For Two New Rapid Tests For The Detection Of Influenza And Respiratory Syncytial Virus | www.medicalnewstoday.com
Author: GLG Expert Contributor
Meridian's new RSV and Influenza A/B testing should provide new weapons for pediatricians during the upcoming flu and upper respiratory infection season.
November 26, 2007
Taisho/Pfizer’s TS-032 for Schizophrenia: A New Player in mGluR Field
Analysis of: Taisho and Pfizer Sign a Letter of Intent for Taisho's Schizophrenia Drug Candidate | biz.yahoo.com
Author: GLG Expert Contributor
Pfizer has tentatively agreed to partner with Taisho to develop and commercialize the new schizophrenia drug TS-032 outside Japan.  This move may support Pfizer’s efforts to expand its share in the antipsychotic market beyond Geodon.
November 21, 2007
AstraZeneca’s Seroquel XR: Acute….Maintenance…What’s next?!
Analysis of: Seroquel XR Receives Approval From FDA for Maintenance Treatment of Schizophrenia | pharmalive.com
Author: GLG Expert Contributor
FDA has recently approved once-daily Seroquel XR for maintenance treatment of adult schizophrenia patients.  Risk of relapse and recurrence of acute psychotic symptoms were 84% less in patients receiving Seroquel XR vs. placebo.
November 19, 2007
The future impact of this approval is unclear
Analysis of: Seroquel XR Receives Approval From FDA for Maintenance Treatment of Schizophrenia | pharmalive.com
Author: GLG Expert Contributor
Because the studies did not compare Seroquel XR to Seroquel, the true impact of the approval of the XR formulation is unclear.

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Next51 to 60 of 215

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-01T17:45:17.637